hotspot -WSS

hotspot

author：entertainment 2025-09-28 05:26:05 Page View：3481

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： A single drug, study failures leave Anavex with nothing but cash
Next article： Psychedelics group wrestles with new pharma identity

focus

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Ahead of JPM, here's who's profiting most in health care

AdobeForalltheflaktheyget,thecountry’sfourbiggestpharmacybenefitmanagersreportedasurprisinglytameave

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Illumina board agrees to spin off Grail, as divestment plans proceed

GrailIlluminasaidMondayafternoonthatitsboardofdirectorshadapprovedaspin-offofitscancertestsubsidiary

hotspot

knowledge

focus

Illumina board agrees to spin off Grail, as divestment plans proceed